Method of treating Crohn's disease by administering a triple combination therapy of anti-integrin antibody, adalimumab and methotrexate
The invention features new a method for treating inflammatory bowel disease, including Crohn's Disease (CD) or ulcerative colitis in a human patient, comprising administering to a patient a combination therapy comprising an anti-α4β7 antibody, a TNFα antagonist, and an immunomodulator.
1. A method of treating Crohn's Disease (CD) in a patient, wherein the method comprises the step of:
administering to a human patient identified as a high-risk CD patient, a triple combination therapy comprising a humanized anti-α4β7 antibody, adalimumab, and methotrexate,
wherein the triple combination therapy is administered to the patient according to the following dosing regimen:
a. an initial dose of 155 to 180 mg of humanized anti-α4β7 antibody as an intravenous infusion, followed by a second subsequent dose of 155 to 180 mg of humanized anti-α4β7 antibody as an intravenous infusion at about two weeks after the initial dose; followed by a third subsequent dose of 155 to 180 mg of the humanized anti-α4β7 antibody as an intravenous infusion at about six weeks after the initial dose;
b. an initial dose of 160 mg of adalimumab as a subcutaneous injection, followed by a second subsequent dose of 80 mg of adalimumab as a subcutaneous injection, followed by a third subsequent dose of 40 mg of adalimumab at about four weeks after the initial dose; and
c. an initial dose of 15 mg of methotrexate;
further wherein the anti-α4β7 antibody comprises an antigen binding region of nonhuman origin and at least a portion of an antibody of human origin, wherein the humanized antibody has binding specificity for the α4β7 complex, wherein the antigen-binding region comprises the CDRs:
Light chain:
CDR1 SEQ ID NO:7
CDR2 SEQ ID NO:8 and
CDR3 SEQ ID NO:9; and
Heavy chain:
CDR1 SEQ ID NO:4
CDR2 SEQ ID NO:5 and
CDR3 SEQ ID NO:6.
2. The method of claim 1 , wherein the humanized anti-α4β7 antibody has a heavy chain variable region sequence of amino acids 20 to 140 of SEQ ID NO: 1 and/or a light chain variable region sequence of amino acids 20 to 131 of SEQ ID NO:2.
3. The method of claim 1 , wherein the humanized anti-α4β7 antibody has a heavy chain comprising amino acids 20 to 470 of SEQ ID NO:1 and a light chain comprising amino acids 20 to 238 of SEQ ID NO:2.
4. The method of claim 1 , wherein the anti-α4β7 antibody is vedolizumab.
5. The method of claim 1 , wherein the high-risk CD patient additionally is administered a dose of corticosteroid.
6. A method of treating Crohn's Disease in a patient, comprising administering to the patient vedolizumab, adalimumab, and methotrexate according to a triple combination therapy, wherein the triple combination therapy comprises
administering vedolizumab at a dose of 155 to 180 mg at weeks 0, 2, and 6, followed by administration every 8 weeks thereafter;
subcutaneously administering a 160 mg dose of adalimumab at week 0, an 80 mg dose of adalimumab at week 2, and a 40 mg dose of adalimumab at week 4 and every two weeks thereafter; and
administering 15 mg methotrexate;
wherein the patient is at high risk of complication from the Crohn's disease.
7. The method of claim 6 , wherein adalimumab is discontinued at week 26.
8. The method of claim 6 , wherein the methotrexate is administered orally.
9. The method of claim 6 , wherein the methotrexate is discontinued at week 34.
10. The method of claim 6 , wherein the patient is a high-risk Crohn's disease patient.
11. A method of treating Crohn's Disease in a patient, comprising administering to the patient vedolizumab, infliximab, and methotrexate according to a triple combination therapy, wherein the triple combination therapy comprises
administering vedolizumab at a dose of 155 to 180 mg at weeks 0, 2, and 6, followed by administration every 8 weeks thereafter;
intravenously administering infliximab at a dose of 5 mg/kg at weeks 0, 2 and 6, and then every 8 weeks thereafter; and
administering 15 mg methotrexate;
wherein the patient is at high risk of complication from the Crohn's disease.
12. The method of claim 11 , wherein infliximab is discontinued at week 26.
13. The method of claim 11 , wherein the methotrexate is administered orally.
14. The method of claim 11 , wherein the methotrexate is discontinued at week 34.
15. The method of claim 11 , wherein vedolizumab is administered at a dose of 155 to 170 mg.